Type 1 Diabetes Mellitus Associated with Nivolumab after Second SARS-CoV-2 Vaccination, Japan

Recently, along with increasing use of immune checkpoint inhibitors such as nivolumab, the incidence of immune-related adverse events, including type 1 diabetes mellitus, has become a serious problem. We report a patient who had immune checkpoint inhibitor‒associated type 1 diabetes mellitus that de...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Toshihiro, Kodama, Shinjiro, Kaneko, Keizo, Imai, Junta, Katagiri, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239866/
https://www.ncbi.nlm.nih.gov/pubmed/35468049
http://dx.doi.org/10.3201/eid2807.220127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239866/
https://www.ncbi.nlm.nih.gov/pubmed/35468049
http://dx.doi.org/10.3201/eid2807.220127

Ejemplares similares